eISSN: 3023-6940
The New Journal of Urology
  • Home
  • Renal abscess in childhood: a case report 6 years girl

Article Tools

Related Subjects

E-SUBMISSION

Case Report

Renal abscess in childhood: a case report 6 years girl


1 Health Sciences University, Ümraniye Training and Research Hospital Pediatric Surgery, İstanbul, Turkey
2 Health Sciences University, Ümraniye Training and Research Hospital Pediatric Infectious Diseases, İstanbul, Turkey
3 Health Sciences University, Ümraniye Training and Research Hospital Pediatric Radiology, İstanbul, Turkey
4 Sakarya University, Faculty of Medicine, Department of Pediatrics, Sakarya, Turkey
5 Health Sciences University, Ümraniye Training and Research Hospital, Pediatric Surgery, İstanbul, Turkey


DOI : 10.33719/yud.2022;17-1-972408
New J Urol. 2021;17(1):58-62
Abstract

Abstract

Erectile dysfunction (ED) is defined as persistent inability to achieve or maintain a penile erection sufficient for satisfactory sexu-al performance. Benign prostatic hyperplasia (BPH)  is often seen at advanced age like ED, and they share a common pathophysiologic mechanism. Both are major health problems that negatively affect the patients’ quality of life. As the first-line treatment, phosphodiesterase type 5 inhibitors (PDE5i) are used for ED, and alpha-blockers for BPH. The using of PDE5i in the treatment of lower urinary tract symptoms (LUTS) due to BPH, has been gaining popula-rity in recent years. Having therapeutic effects for both erectile function and LUTS, PDE5i are good candidates as a monotherapy in BPH pati-ents. In this review, the current status of PDE5i therapy for patients with LUTS due to BPH is discussed.

Key Words: Benign prostatic hyperplasia, erectile dysfunction, phosphodiesterase type 5 enzym inhibitors, prostate

Abstract

Erectile dysfunction (ED) is defined as persistent inability to achieve or maintain a penile erection sufficient for satisfactory sexu-al performance. Benign prostatic hyperplasia (BPH)  is often seen at advanced age like ED, and they share a common pathophysiologic mechanism. Both are major health problems that negatively affect the patients’ quality of life. As the first-line treatment, phosphodiesterase type 5 inhibitors (PDE5i) are used for ED, and alpha-blockers for BPH. The using of PDE5i in the treatment of lower urinary tract symptoms (LUTS) due to BPH, has been gaining popula-rity in recent years. Having therapeutic effects for both erectile function and LUTS, PDE5i are good candidates as a monotherapy in BPH pati-ents. In this review, the current status of PDE5i therapy for patients with LUTS due to BPH is discussed.

Key Words: Benign prostatic hyperplasia, erectile dysfunction, phosphodiesterase type 5 enzym inhibitors, prostate

Creative Commons

LİMRADIGITAL